CardioAcademic

11/11/2025

From JAMA Internal Medicine: A 6-month habit-based group lifestyle intervention led to sustained remission of metabolic syndrome (MetS) at 24 months in 28% of participants, outperforming education and activity monitoring alone.

Improvements included metabolic risk factors, physical activity, and diet habits, highlighting the potential of simplified habit formation for lasting benefits.



https://ja.ma/43iFbX4

11/11/2025

Could your morning brew be heart-smart? ☕ Findings from DECAF presented at found that patients who enjoyed just one cup of caffeinated coffee a day after cardioversion had fewer recurrences of or atrial flutter compared to those who abstained.

Follow ACC's coverage of for more insights ➡️ https://bit.ly/4p2s1pD

11/11/2025

From JAMA: Adding coronary CT angiography (CCTA) data to traditional risk scores and coronary artery calcium scoring improved risk prediction for first coronary events over nearly 8 years of follow-up.

While the clinical impact was modest in a low-risk population, CCTA enhanced risk discrimination and reclassification, particularly among those considered low risk by conventional models.



https://ja.ma/4nIXDiQ

11/11/2025

Statin therapy remains a cornerstone for primary and secondary prevention of major adverse cardiac events (MACEs), but prescribing based on patient phenotype identified through imaging may boost its effectiveness, according to a new study. http://ms.spr.ly/6188tza8Q

11/11/2025

Early Initiation of PCSK9 inhibition with alirocumab ➕ statin therapy safely lowered LDL-C in patients, but didn’t ⬇️ coronary artery plaque progression, based on CAVIAR findings presented at .

Read more: https://bit.ly/444cwVZ

08/11/2025

MAPLE-HCM: Patients with oHCM treated with aficamten saw superior benefits in symptoms, exercise capacity, LVOT gradient and overall health status when compared to metoprolol.

Learn more: https://bit.ly/47wIVqD

JACC Journals

08/11/2025

2️⃣ late-breaking science presentations highlight new treatments for severe hypertriglyceridemia at .

Read how the novel DR10624 medication reduced triglyceride levels ➕ liver fat, and about the benefits of olezarsen in reducing pancreatitis. 🔗 https://bit.ly/47xGfch

08/11/2025

CRISPR-Cas9 ➡️ First-in-Human trial presented at suggests one-time infusion of an investigational CRISPR-Cas9 therapy targeting ANGPTL3 is safe and can reduce both LDL cholesterol and triglycerides. The possibility of a one-time treatment with lasting effects is unprecedented, say researchers.

Read the ACC News Story for more: https://bit.ly/47Nfb7O

08/11/2025

VESALIUS-CV results show evolocumab reduced the risk of first cardiovascular events among patients with atherosclerosis or diabetes and without a previous or compared with placebo.

Read more in our coverage: https://bit.ly/4oBNohQ

08/11/2025

Continuous RV monitoring reveals immediate hemodynamic response to Sotatercept in PAH. https://ahajrnls.org/4qLr07b

08/11/2025

In this cross-sectional analysis of NHANES 2011–2020 data, chronic kidney disease affected 14.6% of US adults and 16.7% of those with cardiometabolic risk factors or cardiovascular disease ( ).

Despite the high prevalence, awareness was low, especially among younger adults, women, and Hispanic individuals.



https://ja.ma/4qPia8i

08/11/2025